Supercharged immune cells take on tough lymphoma
NCT ID NCT03196830
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested a special type of immune cell therapy called CAR-T in 168 patients with relapsed or refractory non-Hodgkin lymphoma. The CAR-T cells were designed to recognize four different targets on cancer cells (CD19, CD20, CD22, and CD30). Patients received the cells after a short course of chemotherapy and were followed for at least two years to see how well the treatment worked and what side effects occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-T cells targeting CD19, CD20, CD22, and CD30
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat non-Hodgkin lymphoma who have run out of standard therapies.
- What could go wrong
- This is a single-arm, early-phase trial without a comparison group, so results may not be definitive. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAR - T CD19/CD20/CD22/CD30 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy shows promise for tough lymphoma cases
- Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
- New cell therapy takes aim at Hard-to-Treat blood cancers
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Supercharged immune cells take on tough B-Cell cancers in early trial
- Can a weekly drug combo outsmart resistant lymphoma?